Here in the media centre you will find a range of resources including our latest and archived press releases, statements from our CEO, speeches and presentations, information on our social media policy, and our photo and video library.

From our CEO

A selection of videos and publications featuring our CEO Sir Andrew Witty.

Speeches & presentations

Find the latest and archived speeches and presentations from GSK’s senior executives.

Press releases

These press releases are intended for business journalists and analysts/investors.
17 April 2014

GSK and Genmab receive FDA approval for Arzerra® (ofatumumab) as first-line treatment in combination with chlorambucil for patients with Chronic Lymphocytic Leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate

GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

17 April 2014

GSK announces approval in Canada for Incruse Ellipta (umeclidinium) as a treatment for COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Incruse™ Ellipta™ (umeclidinium, as umeclidinium bromide) has received market authorisation in Canada for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

16 April 2014

GSK statement on media reports

There has been recent publicity on cases of alleged misconduct by GSK employees in a number of countries. This is a result of details of these cases being made available to the media

Annual Report 2013

Download the 2013 Annual Report

Information for investors